FREQ News and Press, Frequency Therapeutics Inc. From 03/23/21

Gainers: Benitec Biopharma (BNTC) +71%, Hoth Therapeutics (HOTH) +26%, Aerpio Pharmaceuticals (ARPO) +12%, Soliton (SOLY) +11%, China Jo-Jo Drugstores (CJJD) +9%.Losers: Frequency Therapeutics (FREQ) -75%, Windtree Therapeutics (WINT) ...

Frequency Therapeutics (FREQ) slumps 73% premarket after announcing topline, day-90 data from its FX-322 Phase 2a study (FX-322-202).The interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss ((SNHL)) did not demonstrat...

Frequency Therapeutics (FREQ) -71% after releases new data. from two FX-322 clinical studies; plans to advance single-dose regimen.Anixa Biosciences (ANIX) -23% after raises previously announced bought deal offering of common stock to $22.5M.Windtree Therapeutics (WIN...

Interim FX-322 Phase 2a Results Show Four Injection Schedule Had No Discernible Hearing Benefit Separate FX-322 Phase 1b Study Confirms Hearing Improvement from Single Injection Conference call at 8:30am ET today Frequency Therapeutics, Inc. (Nasdaq: FREQ), t...

Results Published in Leading Peer-Reviewed Otolaryngology Journal, Otology & Neurotology Statistically Significant Improvements Observed in Word Recognition Tests in Quiet and in Noise; Suggests Potential to Improve Speech Intelligibility, a Major Unmet Need for Individual...

On the heels of a phase 2a readout of the company's hearing loss treatment, JPMorgan analyst Anupam Rama upgrades shares of Frequency Therapeutics (FREQ) to Overweight. He lifts his price target to $56 from $27, suggesting about 50% upside from current levels.The final readout of da...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Quentin McCubbin, Ph.D., as chief m...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Company to Review FX-322 Clinical Development Program, Progress and Upcoming Milestones for the First Potential Medicine to Treat Sensorineural Hearing Loss Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body...

Event to be Held January 19, 2021 at 8:00 am ET; Will Feature Prominent Otolaryngology and Audiology Key Opinion Leaders Phase 2a Day-90 Readout for FX-322, Frequency’s Lead Product Candidate, for Acquired Sensorineural Hearing Loss Anticipated in Late Q1 2021; End ...